An AI drug specialist zeroes in on rare forms of obesity
Source ↗
👁 0
💬 0
Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially more selectively than — Rhythm Pharmaceuticals’ marketed medicine Imcivree.
Comments (0)